Table II.
Transplant Information and Complications
| Donor Type: Post-Transplant Conditioning | MRD/URD Tacro/MTX N=19 | MRD/URD PT/Cy N=23 | HRD PT/Cy N=17 | Overall p-value |
|---|---|---|---|---|
| Donor Gender (%) | ||||
| Female | 7 (37) | 9 (39) | 10 (59) | |
| Male | 12 (63) | 14 (61) | 7 (41) | |
| Average--BU Target AUC μMol/L/min | ||||
| 4428.3 | 3852.2 | 4064.3 (2 days BU) | <0.0001 * | |
| 3866.7 (3 days BU) | <0.0001 ** | |||
| Cumulative Busulfan Exposure mg*h/L | ||||
| 72.6 | 63.1 | 33.3 ( 2 days BU) | <0.0001 * | |
| 49.2 (3 days BU) | <0.0001 ** | |||
| HLA match (%) | ||||
| 10/10 | 19 (100) | 22 (96) | ||
| 9/10 | 1 (4) | |||
| 8/10 | 2 (12) | |||
| 7/10 | 2 (12) | |||
| 6/10 | 2 (12) | |||
| 5/10 | 11 (65) | |||
| Stem-Cell Source (%) | ||||
| PBSC | 8 (42) | 3 (13) | 2 (12) | |
| BM | 11 (58) | 20 (87) | 15 (88) | |
| Average CD34+/Kg Infused | ||||
| 4.9 × 106 | 4.62 × 106 | 4.79 × 106 | 0.91 | |
| Average CD3 +/Kg Infused | ||||
| 6.5 × 107 | 6.17 × 107 | 4.82 × 107 | 0.99 | |
| Average Days of Engraftment | ||||
| Neutrophils | 12.53 | 16.22 | 16.2 | 0.0002 |
| Platelets | 16.9 | 23.45 | 20.71 | 0.0034 |
| aGVHD III-IV | ||||
| 6 (32) | 0 | 1 (6) | p=0.0014 | |
| cGVHD moderate-severe | ||||
| 8 (42) | 2 (9) | 4 (24) | p=0.042 | |
| Average Time after Transplant (years) | ||||
| 4.44 | 2.74 | 4.2 | 0.0049 | |
| Current Status (%) | ||||
| Off of immunosuppression | 9 (47) | 13 (57) | 10 (59) | |
| On immunosuppression | 5(26) | 7 (30) | 6 (35) | |
| Dead | 4 (21) | 3 (13) | 1 (6) | |
| Alive but lost to follow-up | 1 (5) | |||
*
= comparison with three groups, but limited to 2 BU days for HRD PT/Cy
**
=comparison with three groups, but limited to 3 BU days for HRD PT/Cy
aGVHD indicates acute graft vs. host disease; cGVHD, chronic graft vs. host disease; HLA, human leukocyte antigen; other abbreviations are explained in Table I.